| [13] |
Greenbaum LE, Ukomadu C, Tchorz JS. Clinical translation of liver regeneration therapies: a conceptual road map[J]. Biochem Pharmacol，2020(175)：113847.
|
| [14] |
Forner A, Reig ME, de Lope CR，et al. Current strategy for staging and treatment: the BCLC update and future prospects[J]. Semin Liver Dis，2010，30(1)：61-74.
|
| [15] |
张长坤，张龙辉，王东, 等. 术前肝功能Child-Pugh评分与白蛋白-胆红素评分对肝癌患者肝切除术后肝衰竭和预后的预测价值[J]. 中华消化外科杂志，2018，17(5)：474-482.
|
| [16] |
Iikura M, Suto H, Kajiwara N，et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells[J]. Lab Invest，2007，87(10)：971-978.
|
| [17] |
Gabryelska A, Kuna P, Antczak A，et al. IL-33 mediated inflammation in chronic respiratory diseases-understanding the role of the member of IL-1 superfamily [J]. Front Immunol，2019(10)：692.
|
| [18] |
Boonpiyathad T, Sözener ZC, Satitsuksanoa P，et al. Immunologic mechanisms in asthma[J]. Semin Immunol，2019(46)：101333.
|
| [19] |
Gillibert-Duplantier J, Duthey B, Sisirak V，et al. Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis[J]. Oncogene，2012，31(30)：3516-3524.
|
| [20] |
Marvie P, Lisbonne M, L'Helgoualc'h A，et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans[J]. J Cell Mol Med，2010，14(6B)：1726-1739.
|
| [21] |
Bergis D, Kassis V, Ranglack A，et al. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma [J]. Transl Oncol，2013，6(3)：311-318.
|
| [22] |
Riddiough GE, Christophi C, Jones RM，et al. A systematic review of small for size syndrome after major hepatectomy and liver transplantation[J]. HPB，2020，22(4)：487-496.
|
| [23] |
王瑶，钱叶本. 肝切除术后肝衰竭的早期诊断和预防[J/OL]. 中华肝脏外科手术学电子杂志, 2020, 9(3):206-208.
|
| [1] |
Broering DC, Hillert C, Krupski G，et al. Portal vein embolization vs. portal vein ligation for induction of hypertrophy of the future liver remnant[J]. J Gastrointest Surg，2002，6(6)：905-913.
|
| [2] |
De la Fuente M, MacDonald TT, Hermoso MA. The IL-33/ST2 axis: role in health and disease[J]. Cytokine Growth Factor Rev，2015，26(6)：615-623.
|
| [3] |
Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family[J]. Nat Rev Immunol，2010，10(2)：103-110.
|
| [4] |
Gao X, Chi X, Wang X，et al. IL-33 inhibits hepatitis B virus through its receptor ST2 in hydrodynamic HBV mouse model[J]. Mediators Inflamm，2020：1403163.
|
| [5] |
Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33/ST2 axis in organ fibrosis [J]. Front Immunol，2018(9)：2432.
|
| [6] |
Sun Z, Chang B, Gao M，et al. IL-33-ST2 axis in liver disease: progression and challenge[J]. Mediators Inflamm，2017：5314213.
|
| [7] |
Huan SL, Zhao JG, Wang ZL，et al. Relevance of serum interleukin-33 and ST2 levels and the natural course of chronic hepatitis B virus infection[J]. BMC Infect Dis，2016(16)：200.
|
| [8] |
Wang J, Zhao P, Guo H，et al. Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis C[J]. Mediators Inflamm，2012：819636.
|
| [9] |
Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system[J]. J Hepatobiliary Pancreat Surg，2005，12(5)：351-355.
|
| [10] |
Rahbari NN, Garden OJ, Padbury R，et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS) [J]. Surgery，2011，149(5)：713-724.
|
| [11] |
Johnson PJ, Berhane S, Kagebayashi C，et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade[J]. J Clin Oncol，2015，33(6)：550-558.
|
| [12] |
Takahashi K, Liang C, Oda T，et al. Platelet and liver regeneration after liver surgery[J]. Surg Today，2020，50(9)：974-983.
|